2023 - Research.com Medicine in Denmark Leader Award
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Surgery, Risk factor and Osteoporosis. Internal medicine is closely attributed to Placebo in his research. The study incorporates disciplines such as Cortical bone, Calcium metabolism and Parathyroid hormone in addition to Endocrinology.
In his study, Forearm is strongly linked to Cohort study, which falls under the umbrella field of Surgery. The Risk factor study combines topics in areas such as Odds ratio, Relative risk, Blood pressure, Atrial fibrillation and Type 2 diabetes. His Osteoporosis research is multidisciplinary, incorporating perspectives in Hormone replacement therapy, Age related and Vertebral body.
Leif Mosekilde mainly focuses on Internal medicine, Endocrinology, Osteoporosis, Surgery and Vitamin D and neurology. His work on Placebo expands to the thematically related Internal medicine. His work carried out in the field of Endocrinology brings together such families of science as Calcium metabolism, Parathyroid hormone and Osteocalcin.
His Osteoporosis research is multidisciplinary, relying on both Physical therapy, Menopause and Raloxifene. His studies in Surgery integrate themes in fields like Relative risk, Case-control study, Cohort study and Risk factor. His Vitamin D and neurology study combines topics from a wide range of disciplines, such as Vitamin and Secondary hyperparathyroidism.
His primary areas of investigation include Internal medicine, Endocrinology, Vitamin D and neurology, Hypoparathyroidism and Placebo. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery. The various areas that Leif Mosekilde examines in his Endocrinology study include Calcium metabolism, Parathyroid hormone and Familial hypocalciuric hypercalcemia.
His Vitamin D and neurology research incorporates themes from Vitamin, Myocardial infarction and Animal science. Leif Mosekilde has researched Hypoparathyroidism in several fields, including Postural stability and Epidemiology. His studies examine the connections between Placebo and genetics, as well as such issues in Leptin, with regards to Osteocalcin and Weight loss.
Leif Mosekilde focuses on Internal medicine, Endocrinology, Hypoparathyroidism, Placebo and Vitamin D and neurology. His Methylmalonic acid study in the realm of Internal medicine interacts with subjects such as Trustworthiness. His Hypoparathyroidism study combines topics in areas such as Quality of life, Parathyroid hormone and Pediatrics.
Leif Mosekilde focuses mostly in the field of Placebo, narrowing it down to matters related to Randomized controlled trial and, in some cases, Relative risk, Angina, Meta-analysis and Physical therapy. His biological study spans a wide range of topics, including Myocardial infarction, Acute coronary syndrome, Vitamin and Cohort study. The Bone remodeling study which covers Osteoporosis that intersects with Orthopedic surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial
Louise Lind Schierbeck;Lars Rejnmark;Charlotte Landbo Tofteng;Lis Stilgren.
BMJ (2012)
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk
P. Vestergaard;L. Rejnmark;L. Mosekilde.
Diabetologia (2005)
Effects of thyroid hormones on bone and mineral metabolism.
Leif Mosekilde;Erik Fink Eriksen;Peder Charles.
Endocrinology and Metabolism Clinics of North America (1990)
Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target‐organ involvement, treatment, and challenges for future research
John P Bilezikian;Aliya Khan;John T Potts;Maria Luisa Brandi.
Journal of Bone and Mineral Research (2011)
Vitamin D and the elderly
Leif Mosekilde.
Clinical Endocrinology (2005)
Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis.
T. Hagenau;R. Vest;T. N. Gissel;C. S. Poulsen.
Osteoporosis International (2009)
Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.
Erik F. Eriksen;Peder Charles;Flemming Melsen;Leif Mosekilde.
Journal of Bone and Mineral Research (2009)
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.
P. Vestergaard;L. Rejnmark;L. Mosekilde.
Calcified Tissue International (2006)
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study.
Erik Roj Larsen;Leif Mosekilde;Anders Foldspang.
Journal of Bone and Mineral Research (2003)
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers
Ellen M. Hauge;Dorte Qvesel;Erik Fink Eriksen;Leif Mosekilde.
Journal of Bone and Mineral Research (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Steno Diabetes Center
Aarhus University
University of Southern Denmark
University of Oslo
Finnish Institute for Health and Welfare
University of Western Australia
University of Helsinki
University of Manchester
University of Maryland, Baltimore
deCODE Genetics (Iceland)
Zebra Technologies (United States)
Polytechnic University of Milan
University of Toronto
Harbin Institute of Technology
Trinity College Dublin
University of Murcia
Hokkaido University
Colorado School of Mines
Kobe University
Washington State University
Johns Hopkins University
TU Dresden
University of California, San Diego
Spanish National Research Council
National University of Ireland, Galway
Tokyo Dental College